MOTION - JAPAN: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

Sponsor

Biogen (Industry)

Overall Status

Completed

CT.gov ID

NCT01917019

Collaborator

(none)

101

Enrollment

Locations

Arms

Duration (Months)

5.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multicenter study conducted in 3 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B and C are open-label extension periods. The primary objective of the double-blind study (Part A) is to assess the effect of Prolonged-Release Fampridine treatment on walking speed as measured by the T25FW (timed 25 foot walk) in Japanese participants with Multiple Sclerosis. The secondary objective of the double-blind portion of the study is to evaluate the safety and tolerability of prolonged-release Fampridine in this study population. The primary objective of the open-label extension study (Part B) is to evaluate the long-term safety profile of prolonged-release Fampridine. The primary objective of the additional open-label extension (Part C) is to provide participants who complete the study with continued access to prolonged-release fampridine until marketed drug can be used at the applicable site or until sponsor decision to discontinue the study.

Condition or Disease	Intervention/Treatment	Phase
Multiple Sclerosis, Remittent Progressive Multiple Sclerosis, Primary Progressive Relapsing-Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis Multiple Sclerosis	Drug: Placebo Drug: BIIB041 (fampridine)	Phase 3

Study Design

Study Type:

Interventional

Actual Enrollment :

101 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension

Study Start Date :

Aug 1, 2013

Actual Primary Completion Date :

Oct 1, 2015

Actual Study Completion Date :

Mar 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Part A Placebo Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.	Drug: Placebo matching placebo tablets
Experimental: Part A prolonged-release fampridine Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.	Drug: BIIB041 (fampridine) fampridine prolonged-release tablets Other Names: Fampyra prolonged-release fampridine dalfampridine Ampyra
Experimental: Part B prolonged-release fampridine Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.	Drug: BIIB041 (fampridine) fampridine prolonged-release tablets Other Names: Fampyra prolonged-release fampridine dalfampridine Ampyra
Experimental: Part C prolonged-release fampridine Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.	Drug: BIIB041 (fampridine) fampridine prolonged-release tablets Other Names: Fampyra prolonged-release fampridine dalfampridine Ampyra

Outcome Measures

Primary Outcome Measures

The proportion of participants who show a consistent improvement in walking speed [Part A (Up to 21 Weeks)]
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part B (54 Weeks)]

Secondary Outcome Measures

Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part A (Up to 21 Weeks)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Part A

To be eligible to participate in Part A, candidates must meet the following eligibility criteria at screening or at the timepoint specified in the individual eligibility criterion listed (potential subjects who fail screening may be rescreened 1 time):

Must have a diagnosis of primary-progressive, secondary progressive, progressive relapsing, or relapsing-remitting MS as defined by the revised McDonald Committee criteria ([Lublin and Reingold 1996; McDonald 2001; Polman 2005]) of at least 2 months duration.
Must be able to complete the T25FW with or without a walking aid in 8 to 45 seconds at the screening visit.

Part B

To be eligible to participate in Part B, candidates must meet the following criteria at the

Week 21 visit in Part A, which is the first visit for Part B:

Completed all visits in Part A of the study.

Part C

To be eligible to participate in Part C, candidates must meet the following criteria at the

Week 52 visit in Part B, which is the first visit for Part C:

Completed all visits in Part B of the study.

Key Exclusion Criteria:

Known allergy to pyridine-containing substances, or any of the inactive ingredients of the prolonged-release fampridine tablet
Any prior history of seizures, epilepsy, or other convulsive disorder, with the exception of febrile seizures in childhood, or prior history of epileptiform activity on electroencephalogram.
Any form of renal impairment as defined by a creatinine clearance (CrCl) of <80 mL/min (estimated by the central laboratory).
Known history of cardiac arrhythmia or cardiac conduction disorders requiring medical or surgical intervention, or any clinically significant ECG abnormality (as determined by the Investigator) at the screening visit or Day 1.
Any prior treatment with fampridine (4 AP) or 3,4 diaminopyridine in any formulation.
Treatment with an investigational drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to the screening visit.
Participation in an investigational study (with the exception of observational studies) within 30 days prior to the screening visit or plans to enroll in another interventional investigational study at any time during this study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations

Locations

	Site	City	Country
1	Research Site	Bunkyo-ku	Japan
2	Research Site	Chiba-shi	Japan
3	Research Site	Fuchu	Japan
4	Research Site	Fukuoka-shi	Japan
5	Research Site	Kawagoe-shi	Japan
6	Research Site	Kodaira-shi	Japan
7	Research Site	Kyoto-shi	Japan
8	Research Site	Morioka	Japan
9	Research Site	Niigata	Japan
10	Research Site	Obihiro	Japan
11	Research Site	Osaka	Japan
12	Research Site	Ota-ku	Japan
13	Research Site	Sapporo-shi	Japan
14	Research Site	Sendai	Japan
15	Research Site	Shinjuku-ku	Japan
16	Research Site	Suita-shi	Japan
17	Research Site	Toon-shi	Japan
18	Research Site	Ube-shi	Japan
19	Research Site	Yachiyo-shi	Japan